SCHEMBL9348232

SCHEMBL9348232

COc1cccc(N2C(=O)C3(CCCC3)C(=O)c3cccnc32)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.42
MAPT P10636 5/20 0.42
NPC1 O15118 1/20 0.41
KAT2B Q92831 1/20 0.41
BCHE P06276 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
CACNA2D1 P54289 1/20 0.37
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTR1A P08908 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9352368 0.85 PGR (0.42) MGLLMAPTALDH1A1CYP1A2KMT2A
SCHEMBL9348203 0.84 NPC1 (0.40) MAPTNPC1ALDH1A1KMT2AMEN1
SCHEMBL9628950 0.83 MAPT (0.38) MGLLMAPTNPC1KAT2BBCHE
SCHEMBL9348254 0.83 PGR (0.43) ALDH1A1KMT2AMEN1
SCHEMBL9348253 0.80 POLB (0.44) NPC1ALDH1A1CYP1A2KMT2AMEN1
SCHEMBL10377268 0.80 CACNA2D1 (0.41) MAPTNPC1KAT2BBCHECYP1A2
SCHEMBL9348086 0.80 PGR (0.44) MAPTNPC1KAT2BALDH1A1CYP1A2
SCHEMBL9348228 0.78 PGR (0.55) MAPTKAT2BKMT2AMEN1HPGD
SCHEMBL10686019 0.73 CACNA2D1 (0.41) MGLLMAPTNPC1KAT2BALDH1A1
SCHEMBL10688176 0.72 CACNA2D1 (0.43) MGLLMAPTNPC1KAT2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0338010-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1992-02-05 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0144996-B1 SUBSTITUTED SPIRO PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1990-02-28 EP claimed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP claimed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO claimed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP claimed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO claimed
EP-0144996-A2 Substituted spiro pyridine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions SCHERING CORPORATION (US) 1985-06-19 EP claimed
US-5350755-A Treatment of psoriasis or eczema with naphthyridine derivative SCHERING CORPORATION (US) 1994-09-27 US disclosed
EP-0144996-B1 SUBSTITUTED SPIRO PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS AND COMPOSITIONS SCHERING CORPORATION (US) 1990-02-28 EP disclosed
US-4652564-A Substituted spiro pyridine derivatives as anti-allergy and antiinflammatory agents SCHERING CORPORATION (US) 1987-03-24 US disclosed
EP-0144996-A2 Substituted spiro pyridine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions SCHERING CORPORATION (US) 1985-06-19 EP disclosed